Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Making a noteworthy insider sell on May 1, August J Troendle, CEO at Medpace Hldgs (NASDAQ:MEDP), is reported in the latest SEC filing.
What Happened: Troendle's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 16,930 shares of Medpace Hldgs. The total transaction value is $6,782,987.
Monitoring the market, Medpace Hldgs's shares down by 0.0% at $397.86 during Thursday's morning.
Unveiling the Story Behind Medpace Hldgs Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Key Indicators: Medpace Hldgs's Financial Health Revenue Growth: Medpace Hldgs's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 17.73%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
- Gross Margin: The company faces challenges with a low gross margin of 30.36%, suggesting potential difficulties in cost control and profitability compared to its peers.
- Earnings per Share (EPS): Medpace Hldgs's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.32.
Exploring Valuation Metrics Landscape:
- Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.56 is lower than the industry average, indicating potential undervaluation for the stock.
- Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.45 suggests overvaluation in the eyes of investors, considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Medpace Hldgs's EV/EBITDA ratio, lower than industry averages at 31.56, indicates attractively priced shares.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Breaking Down the Significance of Transaction Codes In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Medpace Hldgs's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.